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Alopecia areata is a suspected autoimmune hair loss
disease. In a rodent model, alopecia areata can be
induced in normal haired C3H/HeJ mice by transfer
of skin grafts from mice with spontaneous alopecia
areata. At weeks 2, 4, 6, and 10 after surgery, grafted
mice were euthanized, skin collected and processed
for histology, and RNA extracted. Age-matched
sham-grafted mice, and mice with and without
spontaneous alopecia areata, were similarly pro-
cessed. For comparison, skin biopsies from alopecia
areata and androgenetic alopecia affected humans
were also collected. Skin mRNA processed to cDNA
was analyzed using Affymetrix mouse 11K and
human 6800 gene chipâ array technology.
Microarray results indicated 42 known genes upregu-
lated or downregulated during onset of mouse alope-
cia areata consistent with an in¯ammatory cell-
mediated disease pathogenesis involving antigen pre-
sentation, costimulation, and a T helper 1 lympho-
cyte response. In contrast, 114 genes, many
regulating immunoglobulin response, were altered
late in disease development. In alopecia areata
affected humans, 95 genes were signi®cantly modu-
lated. As con®rmation of microarray analysis results,
lymph node and spleen cells from alopecia areata
affected mice injected into normal haired littermates
transferred the alopecia areata phenotype. Alopecia
areata onset could be inhibited in skin-grafted mice
by modulation with B7.1- and B7.2-speci®c mono-
clonal antibodies. In addition, depletion of
CD4+ CD8+ expressing cells in chronic alopecia
areata affected mice using monoclonal antibodies
permitted hair regrowth. The results consistently
demonstrated the importance of an immune cell-
mediated disease mechanism in alopecia areata
pathogenesis and suggested targeting antigen-pre-
senting cells and reactive lymphocytes may be effect-
ive in alopecia areata treatment. Key words:
autoimmune/B7.1/B7.2/CTLA-4-mIgG2am/lymphocyte
costimulation/rodent model. J Invest Dermatol 119:392±
402, 2002
A
lopecia areata (AA) in humans is a spontaneous
reversible form of hair loss with a lifetime risk of
1.7% (Hordinsky, 1994; Safavi et al, 1995). The
disease can affect any hair bearing region of the skin
and is seen in men, women, and children. Hair loss
can develop in distinct patches or, occasionally, diffuse areas most
frequently on the scalp. In 7% of cases, alopecia may progress to
total scalp hair loss (alopecia totalis, AT) or total body hair loss
(alopecia universalis, AU) (Safavi et al, 1995). Current concepts of
AA disease pathogenesis suggest AA is a nonscarring, in¯ammatory,
cell-mediated disease. A perifollicular and intrafollicular mono-
nuclear cell in®ltrate of primarily CD4+ and CD8+ cells is closely
associated with dystrophic anagen stage hair follicles (Perret et al,
1984; Ranki et al, 1984) and immunomodulatory agents have been
used to induce hair regrowth (Gupta et al, 1990; Hoffmann et al,
1994). These and other circumstantial evidence suggest that AA
may be an autoimmune disease of anagen stage hair follicles,
although there is no direct evidence in support of this hypothesis
(McElwee et al, 1999c).
A number of species, including several mouse strains, develop
circumscribed hair loss associated with nonscarring in¯ammation of
dystrophic anagen hair follicles (Sundberg et al, 1995; McElwee et al,
1998b, 1999a). Of these, the C3H/HeJ inbred mouse strain has
been identi®ed as a promising mouse model for AA (Sundberg et al,
1994a). The C3H/HeJ strain develops AA-like hair loss with a
spontaneous expression rate of 20% in mice aged 18 mo or older.
Breeding studies indicate that AA-like hair loss has a polygenic
dominant or semidominant basis with partial penetrance (Sundberg
et al, 1994a; McElwee et al, 2001). Whereas a low spontaneous
expression rate is typical of a polygenic disease (Vyse and Todd,
1996; Morel et al, 1994), it limits the usefulness of any spontaneous
mouse model in disease research.
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Recently, a simple AA-induction technique was developed. Full
thickness AA-affected skin grafts from spontaneous AA-affected
C3H/HeJ mice can be used to induce hair loss in naõÈve, normal
haired adult recipients (McElwee et al, 1998a). Typically, 8±10 wk
after surgery, graft recipients will develop ventral and then dorsal
hair loss. This technique is a suitable model to de®ne the dynamics
of AA after the disease activation event, in advance of overt hair
loss, and during the initial stages of alopecia.
In order to examine the kinetics of cellular and molecular events
leading to hair loss, the naturally occurring and skin graft induced
AA mouse models were used. Gene expression patterns were
determined in advance and during the initial stages of hair loss.
These gene pro®ling data were compared with similar data derived
from human patients with the severe forms of AA, AT, and AU. By
using gene expression pro®ling, it was possible to determine the
relative timing of important molecular events and compare these
with those observed in various forms (stages) of human AA.
Although gene array technology is most useful as a large-scale
screening tool, several possible modes of disease induction and
intervention in mouse AA-like disease development were identi-
®ed based on gene array data analysis that were subsequently
selected for further examination. Lymphocyte depletion in AA-
affected mice or transfer of cells from affected to clinically normal
mice revealed these were the primary effector cells. Agents speci®c
for antagonizing lymphocyte costimulation pathways were used in
the mouse skin graft model to determine whether interfering with
these events was suf®cient to prevent disease onset. These studies
demonstrate (i) that the C3H/HeJ mouse model for AA is similar in
many respects to the human clinical disease, and (ii) agents that
block T cell activation through costimulation pathways are
suf®cient to prevent onset of disease in mice.
MATERIALS AND METHODS
Mice Spontaneous AA-affected and AA-unaffected C3H/HeJ mice
were obtained from the Jackson Laboratory (Bar Harbor, ME). All mice
received autoclaved food pellets (NIH 31 modi®ed with 6% fat, diet
code 5K52, PMI, Richmond, IN) and acidi®ed water ad libitum. All
procedures were conducted with Institutional Animal Care and Use
Committee (IACUC) approval. Normal haired mice were grafted with
AA-affected skin using previously described techniques (McElwee et al,
1998a). Age-matched C3H/HeJ mice were killed by CO2 asphyxiation
at 2, 4, 6, and 10 wk after skin grafting. For each time point, four mice
grafted with AA-affected skin and four sham-grafted control mice were
studied. In addition, for gene expression analysis, three mice with
spontaneous, chronic, extensive AA persisting for at least 6 mo were
used as positive controls and three unaffected wild-type littermates were
used as negative controls. Representative skin taken from the graft and
immediately adjacent skin as well as distant sites of dorsal and ventral
skin were ®xed in Fekete's acid-alcohol formalin and processed routinely
for histology (Relyea et al, 2000).
Human AT patients and controls Approval to perform a 4 mm
biopsy with suitable anesthesia and precautions of human scalp skin was
received from the Vanderbilt University Committee for the Protection
of Human Subjects. Three subjects with histologically documented AA
(AU: 30 y old female caucasian, AT: 44 y old female caucasian, and 43 y
old male caucasian), no known hair or scalp skin problems (39 y old
female caucasian, 52 y old female caucasian), and a patient with
androgenetic alopecia (60 y old male caucasian) volunteered. A biopsy of
a site of actively growing hair (chest) was also obtained from the
volunteer with androgenetic alopecia to compare with his nonin¯amed
androgenetic alopecia site. Evaluation of biopsy sites at the time of suture
removal and subsequent follow-up found no complications. In the acute
or subacute stage all AA patients had exclamation point hairs, a positive
hair pull test, and histologically documented AA. At the time of the
biopsies for this study, the patients had chronic, nonscarring AA with no
obvious terminal hairs and no evidence of in¯ammation. No histologic
exam of a portion of the specimens for DNA microarray was done. Four
samples of normal breast skin, removed and discarded at the time of
breast reduction surgery, were also tested.
RNA puri®cation and quantitative reverse transcriptase±
polymerase chain reaction (reverse transcriptase±PCR) and Gene
chip analysis After being euthanized, mice were shaved with
mechanical clippers and total, full thickness dorsal and ventral skin were
dissected free. Underlying fascia and soft tissue were removed. RNA was
prepared by cutting skin into small (2.0 cm) pieces and snap freezing
them in liquid nitrogen. Frozen skin was homogenized in a Pyrex tube
containing Tri-reagent system (5 ml per 2 cm2 skin; Molecular Research
Center, Cincinnati, OH) using a Polytron tissue homogenizer
(Westbury, NY) for 1 min on ice. After RNA precipitation, RNA was
puri®ed using an RNeasy spin column system according to the
manufacturer's instructions (Qiagen, Chatsworth, CA). Puri®ed RNA
was then resuspended in diethyl pyrocarbonate-treated water and stored
at ±80°C until further use. The same procedures were used for human
skin.
Total RNA was then converted to cDNA by priming with an
oligo(dT) primer that included a T7 RNA polymerase promoter site at
the 5¢ end (Lockhart et al, 1996). The cDNA was used directly in an
in vitro transcription reaction in the presence of biotinylated nucleotides
to produce labeled cRNA (anti-sense RNA), that was hybridized
overnight to Gene chips (Affymetrix, San Jose, CA). The mouse 11K
and human 6800 gene chips were used for these studies. After labeling
with phycoerythrin±streptavidin, the ¯uorescence of bound RNA was
quantitated by using a Gene chip Reader (a modi®ed confocal micro-
scope; Affymetrix) and analyzed as previously described (Wilson et al,
2000).
Quantitative PCR Samples were reverse transcribed for 30 min at
60°C and then subjected to 40 rounds of ampli®cation for 15 s at 95°C
and 1 min at 60°C using the ABI Prism 7700 sequence detection system
as described by the manufacturer (Perkin Elmer, Wellesley, MA).
Sequence-speci®c ampli®cation was detected as an increased ¯uorescence
Figure 1. Transfer of alopecia areata from
affected to unaffected mice by skin grafting.
Ten weeks after receiving a full thickness skin
graft from an histocompatible mouse with AA, the
recipient developed AA adjacent to the graft site
(A, B) and at distant site (C, D). Lymphocytes
were present in and around anagen stage hair
follicles. Scale bar: (A, C) 80 mm, (B, D) 20 mm.
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signal of 6-carboxy¯uorescein (6-FAM) during the ampli®cation cycle.
Quantitation of gene-speci®c message levels was based on a comparison
of the ¯uorescent intensity in the unknown mRNA sample with the
¯uorescence intensity from a standard curve of known mRNA levels.
Ampli®cation of mouse glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) cDNA was performed on all samples tested to control for
variations in amounts of RNA. Levels of gene-speci®c messages were
graphed as normalized message units as determined from the standard
curve (Kruse et al, 1997; Trepicchio et al, 1999). A no template control
was included in each ampli®cation reaction to control for contaminating
templates. For valid sample analysis the ¯uorescence intensity in the no
template control was required to be zero.
Cell isolation and transfer Conditioned spleen cells and lymph node
cells from spontaneous AA-affected mice were each examined for their
potential to promote AA. AA-affected and normal haired C3H/HeJ
donor mice were euthanized. Spleens and lymph nodes (axillary,
brachial, super®cial cervical, inguinal) were passaged through sterile
Nitex 110 mesh (Tetko, Lancaster, NY) with Hank's balanced salt
solution (Gibco, Grand Island, NY) on ice. Erythrocytes were removed
from spleen cell populations using hemolytic ACK buffer (8.92 g per l
NH4Cl, 1 g per l KHCO3, 0.32 g per l Na2 ethylenediamine tetraacetic
acid (all Sigma, St Louis, MO) in distilled H2O and autoclaved) for
10 min at room temperature. Nucleated cells were washed by
centrifugation at 200 3 g for 5 min at 4°C and resuspended in fresh
Hank's balanced salt solution. After determining viable cell concentration
by exclusion of 0.1% trypan blue (Sigma), cell samples were resuspended
at 5 3 107 cells per ml.
Cell transfer to immunocompetent C3H/HeJ mice Preliminary
pilot studies suggested AA could be transferred to unaffected C3H/HeJ
mice by a single intraperitoneal injection of 107 lymph node or spleen
derived cells from AA-affected mice; however, overt hair loss typically
did not develop until 14 wk after injection (data not shown). In this
study, 14 mice with spontaneous AA and aged between 6 and 12 mo
were used as a source of spleen and lymph node cells. Of 50 recipients
Table I. Upregulated transcripts (> 3-fold) in mice receiving AA affected skin grafts at 4±6 wk after grafting compared
with no changes in those mice receiving normal, unaffected skin grafts (42 known genes, 16 expressed sequence tags)
GenBank
accession no. Common gene name Of®cial gene symbol/name/type
X69902_s_at Integrin a6 Itga6: integrin a6 (other)
X99807_s_at Selenoprotein P Sepp1: selenoprotein P, plasma, 1 (other)
Z11974_s_at Mrc1 Mrc1: mannose receptor, C type 1 (other)
L20315 Mpeg1 Mpeg1: macrophage expressed gene 1 (macro)
X00619 Tcrb-V13 Tcrb-V13: T cell receptor b, variable chain 13 (T cell)
X00958 I-E (class II) H2-I-Eb (I-E (b-b)) (macro/APC)
X03151_s_at Thy 1 antigen Thy1: thymus cell antigen 1, q (T cell)
X03533_s_at Tyrosine protein kinase p56-tck Lck: lymphocyte protein tyrosine kinase (T cell)
X04648_s_at FcR Fcgr2b: Fc receptor, IgG, low-af®nity Iib (macro/APC)
X14951_s_at LFA-1/CD18 Itgb2: integrin b2 (cd18) (T cell)
X16133_s_at Serglycin Prg: proteoglycan, secretory granule (other)
X16874_f_at Complement C1q b C1qb: complement component 1, q subcomponent, b polypeptide (general immune)
X53247_s_at En-7 (T cell speci®c ras) Rac2: RAS-related C3 botulinum substrate 2 (T cell)
X53526_s_at BCM1/CD48 Cd48: CD48 antigen (macro/APC)
X54511_f_at mbh1 Capq: capping protein (actin ®lament), gelsolin like (other)
X58861_s_at Complement C1q a C1qa: complement component 1, q subcomponent, a polypeptide (general immune)
X62743_s_at Mb H2-DMb1 or H2-DMb2: histocompatibility 2, class II, locus Mb1 or Mb2 (mRNA) (macro/APC)
X66295_s_at Complement C1q c-chain C1qc: complem (general immune)
X67809_s_at Mama (macrophage scavenger
receptor)
Ppicap: peptidylprolyl isomerase C-associated protein (macro/APC)
X72862_s_at b-3-adrenergic Adrb3: adrenergic receptor, b 3 (other)
X75129_s_at Xanthine dehydrogenase Xdh: xanthine dehydrogenase (other)
X84797_s_at HSP-1 (hematopoietic speci®c
protein 1)
Hcls1: hematopoietic cell speci®c Lyn substrate 1 (general immune)
X91144_s_at PSGL-1 Selpl: selectin, platelet (p-selectin) ligand (general immune)
X93037_f_at WDNM-1 Expi: extracellular proteinase inhibitor (other)
X93328_s_at F4/80 Emr1: EGF-like module containing, mucin-like, hormone receptor-like sequence 1 (macro/APC)
Y00635_s_at CD3 Cd3g: CD3 antigen, g polypeptide (T cell)
Z12297_s_at MCP-3 Scya7: small inducible cytokine A7 (general immune)
X97227 CD53 Cd53: CD53 antigen (macro/APC)
X16151 Eta-1/osteopontin Spp1: secreted phosphoprotein 1 (T cell)
U21795 Il2rg IL-2 receptor, g chain (T cell)
L11613 LMP2 proteosome Psmb9: proteosome (prosome, macropain) subunit, b type 9 (large multifunctionalprotease 2)
(macro/APC)
M90397 bcl-3 Bcl3: B cell leukemia/lymphoma 3 (general immune)
M63630 IRG-47 (ifn-g regulated
GTP binding)
I®47: interferon g inducible protein, 47 kDa (T cell)
J00475 IgH chain DJC region Igh-2: immunoglobulin heavy chain 2 (serum IgA) (general immune)
U60087 TAP2 Abcb3: ATP-binding cassette, subfamily B (MDR/TAP), member 3 (macro/APC)
V00832 MHC-II a H2-Aa: histocompatibility 2, class II antigen A, a (k haplotype) (macro/APC)
K01923 MHC-II-Ia-a H2-Aa: histocompatibility 2, class II antigen A, a (d haplotype) (macro/APC)
M86390 Moesin Msn: moesin (other)
U22031 Large multiprotease 7 Psmb8: proteosome (prosome, macropain) subunit, b type 8 (large multifunctional protease 7)
(macro)/APC
U34277 PAF acetylhydrolase Pla2g7: phospholipase A2 group VII (platelet-activating factor acetylhydrolase, plasma)
(general immune)
Y07836 Basic±helix±loop±helix Stra14: stimulated by retinoic acid 14 (other)
X12905 Properdin Pfc: properdin factor, complement (general immune)
L20315 Mpeg1 Macrophage expressed gene 1 (macro)
X00619 Tcrb-V13 T cell receptor b, variable chain 13 (T cell)
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aged 15 wk, 10 females and ®ve males received spleen cells
subcutaneously (sc) and 10 females and ®ve males received lymph node
cells sc. Ten mice received lymph node cells sc and 10 mice received
spleen cells sc from normal haired donor mice, age range 4±6 mo. All
mice received 107 cells in 0.2 ml of Hank's balanced salt solution.
In vivo CD8+ or CD4+ cell depletion in spontaneous AA-affected
C3H/HeJ mice All monoclonal antibodies (MoAb) were produced by
the Jackson Laboratory Monoclonal Antibody Service from publicly
available hybridoma cell clones (American Type Culture Association,
ATCC, Rockville, MD). Rat IgG2b isotype MoAb from clones 53±6.72
and GK1.5 target and deplete mouse CD8+ or CD4+ cells, respectively.
Puri®ed rat IgG (Dako, Carpinteria, CA) was used as a negative control.
Of 21 spontaneous AA-affected mice with an age range of 5±10 mo,
seven received 53±6.72 MoAb, seven received GK1.5 MoAb, and seven
received rat IgG. Each mouse received 100 mg of antibody per injection
on days 0, 3, 7, and 10 in 0.2 ml of phosphate-buffered saline (PBS)
injected intraperitoneally.
Blood samples (» 100 ml) from each mouse were taken by retro-orbital
bleeding on day 0, immediately prior to the ®rst antibody injection, and
subsequently on day 22. Erythrocytes were lysed with hemolytic ACK
buffer and leukocytes washed. Each blood sample was aliquoted and
incubated with saturating concentrations of ¯uorescent isothiocyanate
conjugated MoAb YTS191 anti-CD4+ MoAb or YTS169 anti-CD8+
MoAb. Each MoAb demonstrates noncompetitive binding with MoAb
GK1.5 or 53±6.72. Samples were also simultaneously incubated with
phycoerythrin conjugated H57-597 anti-a/b T cell receptor MoAb. The
cell samples were washed and a ¯uorescence-activated cell sorter ¯ow
cytometer (Becton Dickinson, Sunnyvale, CA) was used to analyze
lymphocyte cell populations using dual color ¯uorescence analysis.
Events were analyzed using appropriate forward and side scatter settings
and gates de®ning the lymphocyte population. Cell viability was assessed
by propidium iodide exclusion. Cell debris and dead cells were excluded
from analysis.
Mice in these studies were monitored from day 0 at the time of
injection onwards by regular examination and macrophotographs taken
to record changes. Mice injected with cells were euthanized after onset
of AA or after 140+ d without apparent phenotypic change. Cell-
depleted mice were euthanized after 50 d. Dorsal and ventral skin were
excised for routine histology at the time of necropsy.
MoAb blockade of lymphocyte activation MoAb directed against
the antigen-presenting cell (APC) surface markers B7.1 (CD80; rat
IgG2a clone 1G10.F9) and B7.2 (CD86; rat IgG2a clone GL±1, Wyeth
Research, Cambridge, MA) (100 mg per mouse) were injected
intraperitoneally 1 d prior to surgery into graft donor mice (those with
and without AA) and future graft recipient mice. Following surgery,
both antibodies were injected at this concentration three times per week
for 4 wk into ®ve female mice that received grafts from female mice
with AA and another ®ve females that received grafts from normal
female mice all of the C3H/HeJ inbred strain. PBS was injected as a
negative control into a second group of ®ve female mice that received
grafts from female mice with AA and another ®ve females that received
grafts from normal female C3H/HeJ mice. In addition, four C3H/HeJ
mice with naturally occurring AA and four that were clinically normal
were injected with these MoAb for a period of 4 wk. Mice were
observed daily and hair regrowth or alopecia were recorded weekly.
Fifteen mice that received AA skin grafts and 15 that received normal
skin grafts were all injected intraperitoneally with 100 mg of mCTLA-4-
mIgG2am per mouse (Wyeth Research, Cambridge, MA) (Steurer et al,
1995; Ling et al, 1998). All mice were injected 1 d prior to receiving the
full thickness graft and then three times a week for 1 wk after surgery. A
third group of 15 mice received skin grafts from AA mice and were
treated the same except they received antibodies for 4 wk after surgery.
Mice were observed as described above. Groups of ®ve mice from both
those receiving AA or sham grafts were necropsied at 8, 16, and 20 wk
after receiving grafts.
RESULTS
Histology Full thickness skin grafts from spontaneous, chronic,
AA-affected mice were surgically implanted onto unaffected,
syngeneic littermates. Only mice with grafts that exhibited no
signs of hair loss due to technical complications were used in this
study. To determine histologic and molecular events in advance of
overt hair loss, total body skin was harvested from mice at 2 wk
intervals after the time of grafting. Because hair loss can begin at
distant locations as well as sites adjacent to the graft, the entire body
skin was removed and used from these mice. Skin distant from the
graft sites with anagen stage hair follicles had perifollicular and
intrafollicular lymphocytic in®ltrates typical of the C3H/HeJ
mouse AA 8 wk after engraftment (Fig 1). No changes were
observed in sham-grafted mice (Fig 1). Detailed histologic and cell
typing studies are presented elsewhere (Zoller et al, 2002).
Gene array analysis of induced mouse AA In order to
understand the molecular kinetic events in the pathogenesis of AA,
RNA was isolated from total skin at the various time points from
AA-grafted and control-sham grafted mice as well as naturally
affected C3H/HeJ mice with long-standing AA. Analyses using the
SubB chip of the Affymetrix mouse 11Kâ chip were performed on
RNA obtained from skin collected at 2, 4, 6, and 10 wk after
surgery as well as from spontaneous, long-standing (chronic) AA-
affected mice. Cluster analysis of the data using a self-organizing
map algorithm showed unique classes of genes that were changed at
different time points (Wilson et al, 2000). Only transcript changes
> 3-fold were considered signi®cant, and one of the genes had to
be ``present'' in at least one of the samples (parameters de®ned by
Affymetrix Gene chip software). Table I and Figs 2 and 3 show
transcripts that were elevated early (4±6 wk after grafting) in the
skin-grafted AA-affected mice. Of 42 known genes present in this
cluster, transcription of T cell marker genes such as Cd3, Cd48,
Cd53, and Selpl was elevated, as were macrophage/APC markers
H2, Emr1, Psmb9, and Abcb3. These expression patterns are
consistent with early immune in®ltrates into the grafts consisting of
both T cell and macrophages/APC. At later time points after
grafting, numerous transcripts encoding a variety of antibody-
variable chain transcripts were observed, suggesting a global
humoral or polyclonal B cell activation response present in these
mice late in the pathogenesis of AA (> 10 wk, Table II).
Collectively, these data provide an overview of the molecular
immune progression of AA in mice, beginning with early markers
of the immune response involving tissue in¯ammation and
vasodilatation, proceeding to macrophage/APC activation and T
cell activation, and culminating in the production of transcripts
associated with antibody production.
Figure 2. Clustering of genes elevated in mice receiving alopecia
areata affected skin grafts. Normalized mRNA frequency (a statistical
transformation of absolute mRNA frequency which allows clustering
independent of expression magnitude) is plotted against weeks after
grafting or in chronic (C) cases (mice with spontaneous, long-standing
AA or age- and sex-matched normal mice). Black lines are data from
mice receiving normal skin grafts (controls) or age-matched mice
receiving normal skin grafts. Grey lines are results from mice that
received AA skin grafts or those with chronic disease. The genes
populating this cluster are listed in Table I.
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The normal pathway of T cell activation requires two main
signals (Bugeon and Dallman, 2000; Salomon and Bluestone,
2001). Signal 1 is achieved through an interaction of the T cell
receptor with antigen in the context of H2 (mouse histocom-
patibility locus)/HLA (human leukocyte antigen locus) complex
molecules, whereas Signal 2 is via CD28 on the T cell surface
interacting with B7 family members on the APC surface.
Transcripts for costimulation genes were slightly elevated.
Quantitative PCR analysis was therefore done to con®rm this
observation using the same mouse skin used for microarray analyses
to ascertain expression level changes in the molecules associated
with T cell activation (Salomon and Bluestone, 2001). As shown in
Fig 4(A,B), transcripts for both B7.1/B7.2 and CTLA-4 are
signi®cantly elevated by 6 wk and 4 wk, respectively, consistent
with the microarray data and the concept that macrophage
activation is coincident or occurs just prior to T cell activation.
Quantitative PCR analysis of other costimulatory pathways was
also done. PD-1 (programmed cell death 1) and ICOS (inducible T
cell costimulator) transcripts were highly elevated during early
disease (Fig 4B). These data show that transcripts for various
costimulation pathways were present in the skin of these mice,
suggesting their casual involvement in the phenotype. We also
wanted to determine if the T cell immune in®ltrate was associated
with a T helper (Th)1 or Th2 cytokine pro®le. As shown in
Fig 4C, early induction of interferon-g (Ifn-g) is observed, whereas
no heightened expression of interleukin 4 (Il-4) was seen. This
pro®le is consistent with a Th1 immune in®ltrate in the skin of AA
mice.
Gene array analysis of chronic human AA To compare
human AA with C3H/HeJ mouse AA, RNA from three patients
and four unaffected age-, sex-, and biopsy site-matched people was
examined using Affymetrix human 6800â chips. Samples were run
individually. The mean frequencies were grouped and analyzed
statistically. Genes that changed < or > 2-fold, with a p < 0.05
between the control and AA patients, are listed in Tables III
and IV.
Biopsies were taken from human patients with chronic,
nonresponsive AA, i.e., those with no active in¯ammation and
relatively few hair follicles/biopsy. Yet, signi®cant immune changes
were observed. In the group of genes that were upregulated in
human AA patients compared with controls, 31 genes ®t the
exclusion criterion used (Table III). Of these, 11 are associated
with lymphocytic in®ltrates. Many genes were suggestive of innate
immunity, such as mast cell markers (Il-8rb, chemokine (C-X-C)
receptor 2, Cmkar2) and the chemokine Mcpt4 (mast cell protease
4), associated with allergic disease, were elevated. Immune markers
associated with T cell in®ltrates were also observed. Granzyme A,
expressed in CD4+ T cells, was elevated in the skin, as was
NFATC3 (nuclear factor for activated T cells, cytoplasmic 3), a
Figure 3. Each gene listed in Table I and summarized in Fig 2 is plotted individually using absolute mRNA frequency to illustrate the
relative strength of each signal. Black lines are data from control grafted mice, whereas grey represent AA grafted mice.
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signaling molecule associated with T cells. Increased STAT1 (signal
transducer and activator of transcription 1) expression is indicative
of Ifn-g signaling as this transcript is often upregulated in Ifn-g
responsive cell types. Interleukin-1 receptor (Il1r1) was also
upregulated, consistent with previous observations of this pathway
playing a part in this disease (Tarlow et al, 1994). In addition, an
array of metabolic, adhesion, and signaling molecules were also
upregulated in these biopsies. Previous association of these
transcripts with AA has not been observed.
The exclusion criteria used de®ned 64 downregulated genes
(Table IV). Of these, 15 are associated with hair keratins or hair
follicles. Many of these transcripts are decreased to the point of
being absent. The remaining downregulated transcripts were
generally associated with either hair follicle or epidermal differen-
tiation and may re¯ect a molecular ®ngerprint of the transcripts'
status in the skin of patients. Not all transcripts speci®cally
associated with hair follicles were downregulated. Transcripts for
trichohyalin were unchanged between control and AA biopsies,
suggesting that not all hair follicle associated transcripts are
downregulated in chronic, dystrophic human AA hair follicles, as
hair ®bers continue to be produced in AA patients. Hair keratins
were also downregulated in mice with long-standing AA
(Table V).
Cell transfer to immunocompetent C3H/HeJ
mice Subcutaneous injection of lymph node cells from AA-
affected mice to normal, haired, immunocompetent C3H/HeJ
mice was an effective promoter of AA. Ten females and two males
of 15 mice (80%) developed ventral and/or dorsal patchy AA
during the study. Hair loss was ®rst observed in eight mice by 5 wk
at the immediate site of cell injection. One mouse had hair loss at
the injection site for the duration of the study but did not develop
further hair loss. Of 11 mice with systemic hair loss (73%), onset
distant to the injection site was ®rst observed 7±10 wk after cell
administration (Fig 5). Hair loss persisted until the time of
necropsy. By contrast, ®ve females and one male of 15 mice
(40%) developed AA with ®rst onset 7±10 wk after sc injection of
spleen cells. sc injection of spleen cells was not associated with hair
loss localized at the site of injection. No mice injected with spleen
or lymph node cells derived from normal haired mice developed
AA during the course of the study.
The histopathology of mice with hair loss revealed perifollicular
and intrafollicular in®ltrates of in¯ammatory cells, primarily
lymphocytes, typical of those observed in C3H/HeJ mice with
spontaneous AA (Sundberg et al, 1994a; Freyschmidt-Paul et al,
1999). Various degrees of in®ltration were observed in different
mice and at different biopsy sites from each mouse as is typical of
the spontaneous disease. In¯ammation was primarily composed of
mononuclear cells. Those with no hair loss had no apparent anagen
hair follicle dystrophy or in¯ammation.
In vivo CD8+ or CD4+ cell depletion in spontaneous AA-
affected C3H/HeJ mice Flow cytometry demonstrated
successful depletion of CD4+ or CD8+ cells from peripheral
blood samples of respective experimental mice (Fig 6, Table VI).
No further immune manipulation was conducted on the cell-
depleted mice. Mice were permitted to regenerate their CD4+ and
CD8+ cell numbers. Of seven mice depleted of CD4+ cells, three
showed signi®cant hair regrowth with the ®rst observation for one
mouse on day 27. Two showed limited, sparse hair regrowth, and
two showed no apparent regrowth of hair. All mice responding to
CD4+ cell depletion showed hair regrowth by 34 d after initiation
of the study. Pelage regeneration reached a maximum by day 41,
although the hair coat was not complete in any mouse (Fig 7).
For seven mice depleted of CD8+ cells, signi®cant hair
regeneration was noted in one and sparse hair growth in three.
Three mice showed no apparent regrowth response. First hair
regrowth was noted by day 31 and all responding mice showed
regrowth by day 41. Of seven control mice injected with rat IgG,
one showed sparse hair regrowth, two showed no apparent
Table II. Upregulated transcripts (> 3-fold) of genes coding for immunoglobulin variable chains in mice receiving
AA-affected skin grafts 10 wk after surgery
GenBank accession no.a Transcript
ET61657 Mus musculus clone 11E6 IgG anti-nucleosome k light chain
ET61730 Mus musculus clone immunoglobulin 2G3.H5 heavy chain mRNA speci®c for mouse cytochrome c
ET61785 Mus musculus anti-DNA immunoglobulin heavy chain IgM antibody 363p.168
ET61855 Mus musculus anti-DNA immunoglobulin heavy chain IgG antibody 423p.135
ET61919 Mus musculus anti-DNA immunoglobulin heavy chain IgM antibody 363s57
ET61989 Mus musculus anti-DNA immunoglobulin heavy chain IgG antibody 423s17
ET62199 Mus musculus immunoglobulin anti-DNA light chain (Vk4/5)
ET62234 Mus musculus polyreactive autoantibody, immunoglobulin IgM heavy chain mRNA
ET62762 Mus musculus anti-von Willebrand factor antibody NMC-4 k light chain mRNA
ET62868 Mus musculus anti-CD8 immunoglobulin heavy chain V region mRNA
ET62983 Mus musculus mRNA for (2F7) IgA V±D±J region
ET63126 Mus musculus mRNA for anti-folate binding protein, MOv19 Vk
ET63276 Mus domesticus IgK variable region (PIR:S26746 immunoglobulin heavy chain J regionJH3-mouse)
GenBank accession no. Common gene name Of®cial gene symbol: name
U22519 Angiogenin-related protein (Angrp) Angrp: angiogenin-related protein
L43568 B cell receptor gene Igh-J: immunoglobulin heavy chain, joining region
Igh-VJ558: immunoglobulin heavy chain (J558 family)
Igk-J: immunoglobulin k chain, joining region
Igk-V5: immunoglobulin k chain variable 5 (V5 family)
X54424 g adaptin Ap1g1: adaptor protein complex AP-1, g1 subunit
X88903 Mus musculus mRNA for variable light Igk-V38: immunoglobulin k chain variable 38(V38) chain
M80423 Mus musculus castaneous. IgK chain gene, Igk-C: immunoglobulin k chain, C-region, 3¢ end constant region
x56602 Ifn-induced 15 kDda protein Isg15: interferon-stimulated protein (15 kDa)
x67783 VCAM-1 Vcam1: vascular cell adhesion molecule 1
x85999 IL-1 accessory protein Il1rap: IL-1 receptor accessory protein
x62742 ± H2-DMa: histocompatibility 2, class II, locus Dma
aTwenty-six additional Affymetrix clones represent different clones for the same antibodies list above. Of 114 known genes, 48 represent transcripts to antibodies.
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regrowth, and four had progressive hair loss. These results suggest
that both CD4+ and CD8+ cells are involved in AA.
Intervention with MoAb In order to ascertain whether the
upregulation of costimulatory and T cell activation molecules was
involved causally in the onset of AA in these mice, reagents known
to diminish T cell activation by preventing B7±CD28 interactions
were used. Full thickness skin grafts from C3H/HeJ mice with AA
to clinically normal C3H/HeJ age- and sex-matched mice
reproducibly resulted in AA in 35 graft recipients. Results are
summarized in Table VII. Treatment of mice with spontaneous
AA with MoAb directed against both B7.1 and B7.2 had no effect
on the clinical disease in four mice. There was no disease induction
in control mice (mice that received normal skin grafts and were
treated with either mCTLA-4-mIgG2am (c2 = 1.185, p = 0.276)
or B7 (NS) there were no signi®cant differences. There was no
signi®cant difference in the treated or untreated mice with or
without (AA). Treatment before the onset of AA, however,
prevented disease in all ®ve mice indicating that the B7 blockade
affects disease (anti-B7 vs PBS results were signi®cantly different
(c2 = 9.0, p = 0.0027) onset but not active lesions. Isotype
controls responded similarly to PBS in previous studies
(Freyschmidt-Paul et al, 2000b). Therefore, B7 blockade does not
reverse the hair-loss phenotype. Similarly, mCTLA-4-mIgG2am
competed effectively with CD28 for B7.2, preventing interaction
with CD28 and thereby preventing onset of AA in 13 of 15 and 14
of 15 mice receiving AA grafts when administered for 1 or 4 wk,
respectively. As there were no statistical differences between
mCTLA-4-mIgG2am used for 1 or 4 wk, these data were pooled.
For mice that received AA skin grafts no treatment was signi®cantly
different from those getting mCTLA-4-mIgG2am (c2 = 53.9,
p = 0.0001).
DISCUSSION
AA can be induced in C3H/HeJ mice by transferring full thickness
alopecic skin grafts from a spontaneously AA-affected mouse to
normal haired, immunocompetent mice (McElwee et al, 1998a).
Initial studies focused on re®ning the criteria needed to generate a
reproducible model (McElwee et al, 1998a). More recently, this
mouse model was used to test compounds that are ef®cacious on
human patients and for determining ef®cacy of MoAb that block
lymphocyte migration and prevent AA (Freyschmidt-Paul et al,
1999, 2000a, b, 2001; Gardner et al, 2000).
The objective of this study was to investigate mechanisms of
disease progression leading to clinical onset and to compare these
results with the spontaneous, chronic form of AA found in the
C3H/HeJ inbred mouse strain. Furthermore, mouse results were
compared with the natural, chronic human forms of AA. Analysis
of gene expression changes in the mouse model were compared
with those in human patients with the chronic forms of AA, AT,
and AU, to determine the degree of similarity between the species.
The kinetic progression of the RNA pro®le changes in the AA
mouse model is consistent with an autoimmune mechanism of hair
loss. Downregulation of hair keratins and hair follicle-associated
genes at 4±6 wk postgrafting is coincident with the presence of
markers of activated macrophages/APC and activated T cells.
Figure 4. Increased costimulatory molecule and cytokine
expression in alopecia areata development. (A) Quantitative PCR
reveals early upregulation of B7.1 and B7.2 transcripts in mice receiving
the AA grafts (AA), whereas those receiving normal, unaffected skin
(sham grafts, S) exhibited no changes. (B) Quantitative PCR revealed an
upregulation of PD±1 as well as CTLA-4 and Icos transcripts 2 wk after
mice received AA affected grafts. No changes were found in these
transcripts in mice that received normal, unaffected skin grafts. (C)
Quantitative PCR demonstrated a marked upregulation of Ifn-g but not
Il-4 transcripts in mice receiving AA affected grafts. No changes were
detected for these transcripts in mice receiving normal, unaffected skin
grafts.
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Table III. Transcripts upregulated (> 2-fold) in human AA patients compared with age-, sex-, and biopsy site-matched
control individuals
GenBank
accession no. Common gene name Of®cial gene symbol: name
Fold
change
M28826 Cd1aa CD1A: CD1A antigen, a polypeptide 2.4
L00389 Cyto-P450 CYP1A2: cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2 3.4
M77140 Galanina GAL: galanin 7.1
M18737 Granzyme A GZMA: granzyme A (granzyme 1, cytotoxic T lymphocyte-associated serine esterase 3) 2.6
U21936 Pept-1 SLC15A1: solute carrier family 15 (oligopeptide transporter), member 1 2.7
J05582 Muc-1 MUCI: mucin 1, transmembrane 2.3
L41067 NFAT C3a NFATC3: nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 3 2.3
U46767 MCP-4 SCYA13: small inducible cytokine subfamily A (Cys-Cys), member 13 3.1
D16294 Mitochondrial coenzyme
A thiolase
ACAA2: acetyl-coenzyme A acyl-transferase 2 (mitochondrial 3-oxo-acyl-coenzyme A thiolase) 6.2
L19593 IL-8Ra IL8RB: IL-8 receptor, b 3.6
U02493 FKBP5 FKBP5: FK506-binding protein 5 4.2
M87770 FGFR2 FGFR2: ®broblast growth factor receptor 2 3.7
X97324 Adipophilina ADFP: adipose differentiation-related protein 5.4
L36529 STAT-1 STAT1: signal transducer and activator of transcription 1, 91 kDa 2.9
X59770 IL-1R2 IL1R2: IL-1 receptor, type II 2.5
U32324 IL-11Ra IL11RA: IL-11 receptor, a 3.4
X67325 ISG 12 (ifn-g induced)a IFI27: interferon, a-inducible protein 27 5.8
aNot present in controls.
Table IV. Transcripts downregulated (> 2-fold) in human AA patients compared with age-, sex-, and biopsy site-matched
control individuals
GenBank
accession no. Common gene name Of®cial gene symbol: name
Fold
change
X86570 Hair acidic keratin 1 (Ha1) KRTHA1: keratin, hair, acidic,1 ± 50
X82634 Hair acidic keratin 3-II (Ha3b) KRTHA3B: keratin, hair, acidic,3B ± 45
X90763 Hair acidic keratin 5 (Ha5) KRTHA5: keratin, hair, acidic, 5 ± 13
X81420 Hair basic keratin 1 (Hb1) KRTHB1: keratin, hair, basic, 1 ± 28
X99141 Hb3 KRTHB3: keratin, hair, basic, 3 ± 17
X99140 Hb5 KRTHB5: keratin, hair, basic, 5 ± 32
Z19574 K17 KRT17: keratin 17 ± 5
X12876 K18 KRT18: keratin 18 ± 4.3
X07696 High-sulfur keratin 1 KRT15: keratin 15 ± 7.3
U42408 Ladinin LAD1: ladinin 1 ± 2.8
M13903 Involucrin IVL: involucrin ± 3.4
Z34974 Plakophilin PKP1: plakophilin 1 ± 3.3
M19888 SPR1 SPRR1B: small proline-rich protein 1B (corni®n) ± 5.8
M20030 SPR2 SPRR2C: small proline-rich protein 2A ± 7.1
L32137 COMP COMP: cartilage oligomeric matrix protein ± 6.8
Table V. Downregulated transcripts (> 3-fold) in mice that received AA affected skin grafts 10 wk after surgery and in
mice with spontaneous, long-standing (chronic) AA (seven known genes, ®ve expressed sequence tags)
GenBank
accession no. Common gene name Of®cial gene symbol: name
U78109 Preproneurturin Nrtn: neurturin
W45778 vWF Vwf: Von Willebrand factor homolog
X85990 Semaphorin A (semaphorin) 3B Sema3b: sema domain, immunoglobulin domain, short basic domain, secreted
AA108571 sim to synuclein Sncg: synuclein, g
M23383 Glucose transporter 2 Slc2a4: solute carrier family 2 (facilitated glucose transporter), member 4
M92088 Type II hair keratinÐHb6 Krt2±10: keratin complex 2, basic, gene 10
M73483 Glutathione-S-transferase Gsta3: glutathione-S-transferase, a3
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These data suggest that the likely mechanism of hair loss in the mice
is initiated by hair follicle-localized antigens being presented to T
cells via activated macrophages. As a small skin graft from an
affected mouse can initiate this entire autoimmune process, it is
possible that the source of immune activation from the graft is
either activated APC, memory T cells, or some antigens present in
the graft itself.
In the above experiments, both spleen and lymph node cells
were capable of promoting AA in C3H/HeJ mice. The delay
between subcutaneous cell injection and systemic alopecia was
similar to that observed with the skin graft transfer of AA (McElwee
et al, 1998a). Transfer of skin-draining lymph node cells was more
effective than spleen cells in initiating hair loss, suggesting that
activated APC or memory T cells from the skin-draining lymph
nodes are the primary cells initiating this entire process. Also, RNA
analyzed from biopsies of human AA patients in this study showed
increased expression of the CD1a Langerhans cell speci®c marker,
suggesting that an ongoing immune response involving APC may
also be involved in human AA.
These data are consistent with earlier studies where blockade of
T cell migration using an anti-CD44v10 MoAb prevented the
onset of AA in the mouse graft model (Freyschmidt-Paul et al,
2000b). Con®rming the crucial role of T cell activation via APC
costimulation, blockade of CD28±B7 interactions and mCTLA-4-
mIgG2am competition with CD28 delayed AA onset. In both of
these systems, histologic analysis revealed hair follicles without
typical lymphocytic in®ltrates. The latter approach was used to
promote islet graft tolerance in mice (Steurer et al, 1995). In vivo
cell depletion in C3H/HeJ mice resulted in transient hair regrowth
or disease stabilization for all C3H/HeJ mice in contrast to control
mice where progressive hair loss was predominant. A hair regrowth
response with CD4+ or CD8+ cell depletion was demonstrated in a
rat AA model (McElwee et al, 1996, 1999b). Both CD4+ and
CD8+ cells may closely interact to maintain an AA lesion. These
observations suggest that disintegration or collapse of hair follicle
integrity does not invoke the immune response, rather that the
immune system is initiating a hair-follicle speci®c attack. Consistent
with these data, the earliest markers of perturbation of gene
expression in the skin of AA mice involve the cell-mediated
immune system, not hair follicle associated gene expression
changes.
As in AA-affected humans, C3H/HeJ mice with spontaneous or
graft-induced AA make transcripts for antibodies directed against
many self antigens (Tobin et al, 1994, 1997a, b). The probes
recognize transcripts previously characterized to produce antibodies
against antigens such as DNA (Mohan et al, 1998; Sobel et al, 1999).
Furthermore, the antibody transcripts are directed toward virtually
every immunoglobulin isotype. This suggests that the C3H/HeJ
mouse has a global propensity towards autoimmunity that is
initiated within the hair follicle but then quickly spreads to many
self antigens. A similar phenomenon has been observed for
antibodies to enteric bacteria associated with the sensitivity of
C3H/HeJ mice to in¯ammatory bowel disease (Sundberg et al,
1994b; Brandwein et al, 1997). Furthermore, C3H/HeJ mice have
a defective response to bacterial lipopolysaccharides (Poltorak et al,
1998; Qureshi et al, 1999), due to a mutation in the Toll4 receptor,
indicating these mice have abnormal innate immunity. This may be
true in humans as well, as humans with AA may have other
autoimmune diseases such as vitiligo, systemic lupus erythematosus,
autoimmune thyroiditis, in¯ammatory bowel disease, and other
diseases (Werth et al, 1992; Treem et al, 1993; McElwee et al,
1999c). Although these data suggest that both the human and the
mouse diseases are autoimmune in nature, the primary disease-
Figure 5. Transfer of alopecia area with injection of lymph node
cells. Normal haired C3H/HeJ recipient (A) of lymph node cells. Ten
weeks later this mouse developed extensive alopecia over the head,
dorsal thoracolumbar region (B), and entire ventral surface (not shown).
Figure 6. Fluorescence activated cell sorter analyses con®rm cell
depletion. Analysis of peripheral blood from three separate mice prior
to injection (day 0; A, C, E) and 22 d after injection (B, D, F) with
MoAb. These antibodies selectively depleted CD8+ (B) or CD4+ (D)
lymphocytes, whereas normal rat immunoglobulin had no effect (F).
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activating target remains elusive. Consequently, a conclusive
statement on the nature of AA pathogenesis cannot be made.
Expression pro®ling of human AA biopsies revealed the presence
of changes associated with chronic, innate immunity, including
expression of surface markers for mast cells as well as the chemokine
MCP4. Although it is dif®cult to obtain human hair follicle biopsies
in early stages of AA and impossible to obtain biopsies in advance of
overt hair loss onset, the mouse data suggest that the initiation phase
of this disease phenotype is a heavily Th1-biased immune response.
Some genes upregulated in human biopsies are consistent with an
immune in®ltrate containing Ifn-g driven, Th1 T cells (NFATC3,
STAT1a). High levels of Ifn-g and Ifn-g-associated transcripts were
detected con®rming previous observations about the expression of
Th1-related genes in human biopsies (Hoffmann et al, 1994). Genes
associated with more generalized, innate immune responses were
detected in human biopsies (e.g., Il8rb, Mcpt4). Many persistent
in¯ammatory diseases initiated via Th1-directed mechanisms
become Th2 in the chronic state (HogenEsch et al, 2001). This
would suggest that maintenance or lack of outright destruction of
the hair follicles by cytotoxic cells may be due to a shift from a Th1
response to a more chronic Th2 immune pro®le. These studies
suggest that in the C3H/HeJ mouse model AA is a cell-mediated
autoimmune disease with late, possibly secondary, humoral
responses. Blockade of parts of the lymphocyte costimulatory
cascade prevents onset of AA in the mouse graft-induced model
suggesting that similar approaches in human patients will prevent
the development of new lesions. By contrast, targeting lymphocytes
should control and resolve existing lesions. Gene array derived data
have provided a signi®cant insight into AA and the technology is
potentially a powerful aid to understanding other chronic in¯am-
matory diseases.
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